Even Low dose diclofenac not risk neutral for cardiovascular events

A study was done to examine the dose dependency of diclofenac’s cardiovascular risks.

Using Danish health registries and the target trial emulation design, we conducted a series of 300 nationwide cohort studies during 1996–2020, each mimicking the strict design criteria of a clinical trial. Adults eligible for inclusion had no recent non-steroidal anti-inflammatory drug prescriptions, contraindications (gastrointestinal diseases, thrombocytopenia, or heart failure), or conditions with low adherence (dementia or psychiatric disease). Diclofenac initiators were compared to healthcare-seeking non-initiators and head-to-head using an approximated high dose of ≥150 mg/day vs. low dose of <150 mg/day. Cox regression was used to compute the incidence rate ratio (IRR) of major adverse cardiovascular events (MACE) within 30 days following initiation. They adjusted for age, sex, calendar period, comorbidity, comedication, and socioeconomic position. Compared with non-initiators (n = 3 789 617), diclofenac initiators (n = 1 894 834) had an approximately 50% increased rate of MACE (IRR 1.53, 95% confidence interval [CI]: 1.43–1.63), reflecting IRRs of 1.54 (95% CI: 1.40–1.69) for myocardial infarction, 1.29 (1.14–1.45) for ischaemic stroke, and 1.92 (1.71–2.16) for cardiac death. The risk increase was observed for most conditions with chronic pain, in particular headache (IRR 5.10, 95% CI: 1.46–17.85). The risk increase was similar for initiators of high- (IRR 1.55, 95% CI: 1.40–1.71) and low-dose diclofenac (IRR 1.52, 1.41–1.63), which was confirmed in a head-to-head analysis (IRR 1.01, 95% CI: 0.90–1.12).

Initiators of high- and low-dose diclofenac had comparably increased cardiovascular risks. This finding provides evidence against the assumption that low-dose diclofenac is risk-neutral.

Reference:

Morten Schmidt, Lars Arendt-Nielsen, Ellen-Margrethe Hauge, Henrik Toft Sørensen, Lars Pedersen, High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation, European Heart Journal – Cardiovascular Pharmacotherapy, 2023;, pvad018, https://doi.org/10.1093/ehjcvp/pvad018